Martin S Naradikian
Overview
Explore the profile of Martin S Naradikian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller A, Kosaloglu-Yalcin Z, Westernberg L, Montero L, Bahmanof M, Frentzen A, et al.
Sci Transl Med
. 2024 Feb;
16(736):eabj9905.
PMID: 38416845
The clinical impact of tumor-specific neoantigens as both immunotherapeutic targets and biomarkers has been impeded by the lack of efficient methods for their identification and validation from routine samples. We...
2.
Brightman S, Becker A, Thota R, Naradikian M, Chihab L, Soria Zavala K, et al.
Nat Immunol
. 2023 Jul;
24(8):1391.
PMID: 37464051
No abstract available.
3.
Brightman S, Becker A, Thota R, Naradikian M, Chihab L, Soria Zavala K, et al.
Nat Immunol
. 2023 Jul;
24(8):1345-1357.
PMID: 37400675
CD4 T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8 T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8 T...
4.
Tokatlian T, Asuelime G, Naradikian M, Mock J, Daris M, Martin A, et al.
Cancer Res Commun
. 2023 Mar;
2(1):58-65.
PMID: 36860694
Significance: We report an effort to generate high potency, selective CARs directed at mutant KRAS peptides. Although the heavily optimized CARs maintain high selectivity against wild-type KRAS, they lose selectivity...
5.
Brightman S, Naradikian M, Thota R, Becker A, Montero L, Bahmanof M, et al.
JCI Insight
. 2022 Dec;
8(2).
PMID: 36512410
CD4+ T cells play a critical role in antitumor immunity via recognition of peptide antigens presented on MHC class II (MHC-II). Although some solid cancers can be induced to express...
6.
Mock J, Winters A, Riley T, Bruno R, Naradikian M, Sharma S, et al.
Mol Ther Oncolytics
. 2022 Nov;
27:157-166.
PMID: 36381658
Innovative cell-based therapies are important new weapons in the fight against difficult-to-treat cancers. One promising strategy involves cell therapies equipped with multiple receptors to integrate signals from more than one...
7.
Tokatlian T, Asuelime G, Mock J, DiAndreth B, Sharma S, Toledo Warshaviak D, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35091455
Background: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a...
8.
Johnson J, Rosenthal R, Knox J, Myles A, Naradikian M, Madej J, et al.
Immunity
. 2020 May;
52(5):842-855.e6.
PMID: 32353250
B cell subsets expressing the transcription factor T-bet are associated with humoral immune responses and autoimmunity. Here, we examined the anatomic distribution, clonal relationships, and functional properties of T-bet and...
9.
Brightman S, Naradikian M, Miller A, Schoenberger S
J Leukoc Biol
. 2020 Mar;
107(4):625-633.
PMID: 32170883
The goal of precision immunotherapy is to direct a patient's T cell response against the immunogenic mutations expressed on their tumors. Most immunotherapy approaches to-date have focused on MHC class...
10.
Pardi N, Hogan M, Naradikian M, Parkhouse K, Cain D, Jones L, et al.
J Exp Med
. 2018 May;
215(6):1571-1588.
PMID: 29739835
T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this study, we characterize...